Genelux Corporation
GNLXHealthcare|Biotechnology|US
$1.96
+0.14 (+7.69%)
Tangible Book / Share
$0.36
Cash / Share
$0.42
About
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Stock Price
-63.0%(1Y)
1M
-21.6%
3M
-26.3%
6M
-37.0%
YTD
-55.0%
1Y
-66.7%
3Y
-86.2%
5Y
-68.1%
Pipeline Summary
10 total trials7
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
Terminated: 1Recruiting: 3Completed: 5No Longer Available: 1
Active Trials (3)
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT06463665Advanced Non-squamous Non-small-cell Lung Cancer
Phase 2Recruiting
Enrollment: 142 participants
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT05281471Platinum-resistant Ovarian Cancer
Phase 3Recruiting
Enrollment: 186 participants
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
NCT07136285SCLC, Extensive Stage
Phase 1Phase 2Recruiting
Enrollment: 27 participants
Key Facts
Market Cap$88.7M
Employees25 (+4% YoY)
CEOThomas D. Zindrick
IPO DateJan 26, 2023
Beta0.58
52-Week Range$1.77 – $6.26
Avg Volume308,566
ExchangeNASDAQ
Websitegenelux.com
Ownership
Float80.7%
Shares Outstanding45.2M
Recent Insider Trades
Cappello JosephSELL
Nov 3, 2026668 shares @ $2.04
Zindrick ThomasSELL
Nov 3, 20263,089 shares @ $2.05
Yu YongSELL
Nov 3, 2026668 shares @ $2.01
Cappello JosephSELL
Aug 31, 202610,257 shares @ $2.74
Zindrick ThomasSELL
Aug 31, 202634,463 shares @ $2.67
Peers
Recent News
Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)
Oct 16, 2026 · defenseworld.net
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
Sep 9, 2026 · globenewswire.com
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
Aug 13, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:12 AM